(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 283.58% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 26.17%.
Renovorx's revenue in 2025 is $662,000.On average, 6 Wall Street analysts forecast RNXT's revenue for 2025 to be $47,199,899, with the lowest RNXT revenue forecast at $22,230,126, and the highest RNXT revenue forecast at $67,794,885. On average, 5 Wall Street analysts forecast RNXT's revenue for 2026 to be $194,956,103, with the lowest RNXT revenue forecast at $161,608,348, and the highest RNXT revenue forecast at $230,869,069.
In 2027, RNXT is forecast to generate $1,581,453,124 in revenue, with the lowest revenue forecast at $430,955,596 and the highest revenue forecast at $3,353,721,366.